An Observational Study of Glucocorticoid Use in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab)

Roche

Status: Completed

Conditions: Rheumatoid Arthritis

Study type: Observational

Funder types: Industry

Identifiers

NCT01392001

ML25634

Details and patient eligibility

About

This observational study will evaluate the glucocorticoid sparing effect after 12 months of treatment with RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Data will be collected for 12 months after the initiation of treatment with RoActemra/Actemra from patients who had been on treatment with >5 mg prednisone or equivalent for at least 3 months .

Enrollment: 322 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/= 18 years of age
• Patients with rheumatoid arthritis for whom the rheumatologist decided to introduce RoActemra
• Patients taking more than 5 mg/day of oral prednisone (or equivalent) for at least 3 months

Exclusion criteria

• Participation in a clinical trial in rheumatoid arthritis

Trial design

322 participants in 1 patient group

Cohort